WAT - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. Welcome to the Waters Corporation Third Quarter 2017 Financial Results Conference Call. All participants will be able to listen-only until the question-and-answer session of the conference. This conference is being recorded. If anyone has objections, please disconnect at this time. pleasure the my Mr. over now is to call turn to It Lynch, Relations. Investor President John of Vice Sir, begin. you may

John Lynch

Thank you, Conference operator, welcome to and good morning Waters Third to Corporation Quarter Earnings Call. the everyone, and

cover Before we cautionary the begin, language. will I

the provide all make forward-looking will future guidance future performance regarding statements call, In company. or various of events possible of the conference future particular, During materially. course for financial we company this regarding We results fourth we statements and income will full predictions the XXXX. that results that statement year events caution you and quarter the such only are or of actual may differ

caution and this guidance earnings For company a in We the further during scheduled release providing XX-K plan caption, predictions. results do We for in possible XXXX. income itself cautionary update the call to is calls performance contingencies actual to under next and detailed differ December statement quarterly the language Part included fiscal significantly X does press year or planned and not Annual commit webcast for regularly risks Report future ended you conference currently except not predictions morning's to present discussion webcasts. XX, our by some the from regarding XXXX Risk could obligate see our X-K. of that and release The cause our this Factors, our of the update expectations, release earnings that and January XX,

increasing references included directly measures or those attached earnings release. results otherwise, as this of schedule non-GAAP non-GAAP we Unless of our which measures comparison reconciliation in morning. to Adjusted Financials the the company's call, results, During say Quarterly decreasing financial quarter non-GAAP GAAP GAAP in the release we financial to of refer be is such most measures. the our the impact In we of may today's XXXX. to to A the this titled year in operations, morning's Reconciliation issued third discussions certain pro-forma items of will referring results outlined quarterly to to exclude to are press of fiscal comparable

including In all given on addition, currency call basis. ranges growth today's on a rates unless say given growth are comparable year-over-year revenue revenue otherwise, constant we

Now Chris over I'd the Chris? like to call Waters' to Executive turn Chief Officer, O'Connell.

Christopher O'Connell

joining Thanks, John, Officer. Along with for good on Lynch, Waters' Financial you morning's everyone joining Buck, John us morning, call is thank and this Sherry me today. Chief

will overview as financial and and our our business. I call, as Sherry the today's our QX outlook. financial an well will on some broader of XXXX then commentary and on an provide update reported QX During operating review provide full-year results results year-to-date for details

the for delivered results, third will of revenue from all major of between the saw product our in balanced and Asia Q&A. we Europe, We we continued each with as then well across growth sequential recurring lines up where we In revenue. another pleased defined as quarter of our States. very United strength instrumentations Geographic major our customer importantly are quarter in and improvement and open lines, markets, summary, solid well end

two Third growth quarter XXXX, results which in the totaled XXXX. leverage and per quarters to and share quarter very up X% consistent in of been upon nicely revenue led for XX% and our a double-digit consistent QX compared X% the This earnings strong featuring performance year-to-date year-to-date. XX% P&L growth same of revenue the built to operating has were period quarterly previous of

market a the look strong of low and prior free starting review to quarter bringing the year. another delivered a at our encouraging comparison we in categories growth year-to-date in of quarter cash to our XX%. which Taking is Additionally, flow category against free base flow with corporate sales broadly strong X% grew in cash our the a level, of pharmaceutical defined teen closer

India in growth headwinds pharmaceutical was caused by customers' in to from sales balanced the disasters strong Geographic GST. systems markets research in or the tax and of accommodate the services biomedical and year emerging goods natural and between growth delays some X% was Year-to-date our Americas against we applications. timing strength our the large implementation markets prior molecule overall our led pharmaceutical for protocols meaningful absorbed and performance. by also Our up new developed were and

core food, Sales applications within our which industrial grew characterization, environmental category markets growth standards, by and require the vast strength quarter material positioned includes more medical the we increasing encouraging industrial characterization. emphasize testing X% well methods. to fine have business to X%. are where Overall, to continues analytical demanding rising across therapies believe volumes global growing work benefit access chemical our in strategy and our sales growing in biologic of materials patient regulatory seen we are the where pharmaceutical opportunities year-to-date ongoing very Our in to we that from therapies led worldwide markets

Looking at we with spending academic sales major in from institutions focused Omex academic based across in the by biomedical XX% performance experienced broad and geographies. QX and saw on strength our all In research. governmental category, grow quarter, we

LC to Waters year-to-date. branded review line highlight grew are and led our in would in Within quarter sales Waters X% continues the solidly mass instruments, the consistently growing spec and bench to overall Mass our will like year-to-date. I systems I as by TA well higher-end GVO dynamics TQXS TQX Now quarter particularly the GVO grow instruments within specs product third tandem Micro. and top our X% workflow as brands.

indicative Quad primarily spec continue safety routine mass and on The the our driven of XX% molecules. Recurring use at Waters Waters service, and our both complete now and of of recurring tandem, workflows commented were and revenues has base large to in chemistry platform service applications. revenues see X% the approximately and to evolving combination offerings. chemistry quantification HPLC of As installed service biopharmaceutical and rates kits the branded business. capabilities high UPLC application of of small in [zero] development X% our we Waters us reproducible our utilization our quantification represent into demand for food revenues technology the expansion precision chemistries for for have instruments. our Year-to-date we of strength global enabled past, grew have and meet quarter grown by

by result benefitted Turning thermal and in to line our quarter TA growth from X% high our by new systems. in lines, of to product Instrument growth bringing sales of in thermal be the grew temperature X%. quarter analyzers XX% for the also XXXX. strong quarterly and discovery to grew TA the year-to-date rheology This led introduced our continue sales

on in innovation high engineered, to materials. well capitalize market trends are performance We rising of positioned highly

Finally, I at the will corporate review level. our performance by geography

China reach Asia, which by faster in as revenue Japan. again led grew X% grew our largest by as well terms of

China solid Our a all saw from of growth our operation markets. core

requirements and Within environmental growth new experienced Drug and industrial the customers Administration. China’s testing from strengthened our the academic customers. to pharmaceutical from across strong Food customers. benefit growth Japan and to category In category, materials growth regulatory for include and continue governmental drivers continue China pharmaceutical food characterization, steady

continued performance over mentioned India Indian overall our expect reporting disruptions situation new smooth we with the GST of out couple next the in in of quarters, the As customers, implementations business. our solid this of associated quarter, results system to impacted previously, with

line Macroeconomic policy in natural our Americas. are sales that U.S. Turning governmental disasters business headwinds steady persist, from to broader sequential States, affecting recent we region. the the quarter, up seeing were we last X% improvement the about in the and talked in Sales with with United flat quarter, expectations. despite uncertainties general still in activity our but

strong our contributor We growing in based are Europe and to the a position. quarter, looking the We continued where for growth our on saw was product we third with with improvement strength sales trends categories and across and well market the highlighted a by our throughout bio-molecule U.S. from XX%, targeted growth are in applications region. customers, solution. broad-based separation LCMS positioned product pharmaceutical bio-pharma strong

saw with strong the also installed service to in from able base to of our We quarter systems. spend on I this sometime large region and further employees. growing and was customers Europe, Commenting revenue

Brasov highlight Eastern has years, one worldwide, this became of site Technology into System steadily operations, a Informatics trip European separation addition to my our of of TA The high well as a as over the the was Waters Chromatography development Software In deep Romania. of and into to team Center instrument visit Lab Water supporting our in Brasov Systems, top development dive Data potential grown Excellence, operational the this LCMS Unified Empower recently of and Management our sites New drivers. Genesis

a new collaboration dedicated enable designed modern facility visit my to we and During innovation.

is informatics for differentiator is offering Waters significant to a a Our and strength. key this Brasov contributor

of quarters results we year. head first line pleased am of has and delivered the three for stretch as into I the with top consistent the line home XXXX, company the bottom So, the

We steadfastly also creation on focused value remain model. five-point our

in shareholder communicated, we have by attractive a and value first differentiated create I holding As position markets. unique structurally constituently to aim highly

Second, growth innovation. executing driven organic clear a by strategy

Third, seeking a disciplined for allocator operating and being oriented operational opportunity Fourth, with capital continuous performance improvement. team. fifth and management a culture

regarding the Finally, effective of of Doug Chairman on as XXXX. Chairman announcement X, last I’d January Board the election week's my the retirement comment like and to of Berthiaume Directors as new

as shareholders Water’s as community. achievements have leader, profoundly and the and built significant Chairman our broader customers, and who value Doug, the modern a visionary employees, His You for impacted all shareholders. know CEO created

broadly has cadence a practices advice rigorous continue strong productive mentor we’ll has for as good him lead a On director. to and and orchestrated me During personal example independent for a in I utilize grateful transition. his for Waters smooth Non-Executive Board meetings, been my the model always and am role with view, past counsel. for robust been a transparency support two his and corporate and a years governance and to in his Doug invaluable level, More Chairman,

to of part to ensure his capabilities Directors governance Pharmaceuticals Sherry Waters. am to highest backgrounds lead program. development resulted participated the our our Sherry? now financials. position to as like underway in with of our Furthermore, enhance board continue new look as our and Ornskov, will the As and of ensure governance insights Director our develop the Buck deeper CEO for for our I initiative forward in working practices. will in that call the board Shire Flemming to review pass I to meetings pleased closely effectiveness over very already and to has recruitment two added of Board, ongoing to continue quarter that, This has of continuing Flemming third With I’d has a optimal and Tom quality the our valuable a mix Dr. of to team. Director management and of practices. I possible Board efforts sustain this, continuously Salice new

Sherry Buck

instrument LC see X% X% our of results and up system sales growing the product in line we In and the again an before X% in LCMS also grew of chemistry growth quarter up further, about and products growth academic recurring currency Chris to with third as TA’s that to morning, quarter while in precision the the services while reported which continue relating instrumentation and customers by was grew about combination quarter. revenue million, strongest you, sales Product recorded branded by X% instrument introduction. X%, and Combined Breaking in and down $XXX increased and X% and net sales of good increased sales Thank markets translation revenue everyone. sales products X% sales We quarter, TA's to service increase grew XX% X%. industrial the benefits of grew pharmaceutical X% growth. new the our were were markets platform sales grew governmental Waters' XX%. sales X%

Our Waters TA and recurring products X%. by with both revenues total associated grew

Japan. flat US currency the sales sales third before growth and our were with were geographically, the rates up in increasing Sales at led were in Americas by China in growth translation, and in X%. Asia up sales X% European in strong Looking the quarter XX%.

result third Now were pound basis year. our XX quarter product of performance for offset headwinds the of higher prior as the currency in cost UK margins Positive approximately points manufacturing mix at I XX.X%. euro. would like the versus to non-GAAP by efficiencies comment steady the a Growth coming and quarter were from on and dynamics

quarter’s up were a expenses the Operating basis. currency P&L. on third constant down Moving X%

have increased Foreign operating grown faster sales Year-to-date operating than currency expense expenses. on X% the by about growth about a X% translation reported basis.

new rule interest year. from benefit million rate non-GAAP XX%. front, stock $X.XX a This entity tax Including the tax the operating the quarter. rules, about is the the of compensation was option about In tax expense $X accounting was from million the in quarter, stock of was XX%. quarter effects down effective the mix the the of On new effective $X result net our rate before about legal process for operating

our Our a lower third XX.X repurchase shares last net average at the year. count is in quarter share than or effect in of share This shares XXX,XXX came million approximately program. ongoing

bought During we for $XX the of third stock shares quarter, our million. common X,XX,XXX

rules. the basis, benefit our versus currency neutral. our earnings comparison $X.XX $X.XX, to from Our up release, of third issued in GAAP to non-GAAP the of impact accounting share GAAP this earnings earnings in to foreign is both quarter year. were of compensation last non-GAAP keeping per diluted reconciliation a A a on share $X.XX GAAP impacts of were non-GAAP The $X.XX in earnings included morning. year. quarter a last On to year-to-date $X.XX. our positive stock new attached the the earnings $X.XX, our earnings press translation about per were resulting XX% and

our million and quarter at receivable XX%. days In cash us excluding approximately down quarter performance $X.X billion of We inventories million compared efficiency define capital debt which from as expenditures. less improvements to at both and expenditures This approximately expectations. year-to-date of days special the contributed of and a of cash cash $XXX items. cash million strong stood net in after two flow of QX was three Modest operations, free the from totaled the was and second bringing prior position XXXX, came the quarter and were cash to Turning sheet, of represents growth totaled outstanding flow year. disciplined billion, cash in Accounts working capital $XXX capital XX sales million $XX strong $XXX and to line days quarter year the quarter, the quarterly to this $X $X.X this year of which third with In investments compared short-term billion. our to third days is generation. in and spending a capital funding in balance last

I’d As year share we XXXX the forward guidance. look like full to to the quarter balance year, fourth our of and

Our be assumes revenue. of recurring global neutral to expected outlook year. to and to constant our by to volume end and Bringing with the year. full altogether currency consistent this increase rates, to growth continued X% At currency sales assumed markets X% in for generally from the demand translation be from the continue gains current foreign growth for XX.X% we negative expect our to consistent currency for translation. full XX%. Higher previous for outlook the offset manufacturing gross in year and margins to range our efficiency effects are Out is guidance, continue is

Our that operating plan for is continue managing a growth. the year than expense growth less at is sales to rate our

$X.XX reflect an price. operating this $XX variation stock option assumed We timing net will the to comprised to accounting and quarter interest our expected stock be is Quarter-to-quarter about year-to-date plus new fourth full tax $X.XX actual per expense be in of the stock our an is earnings of exercises This benefit $X.XX year rate to expected XX%. below line, realized amount of million. year. benefit Moving the approximately share to estimate of of approximately approximately due income rules, including option

We of a with to continue reconciliation item provide remainder this of XXXX.

fully to within to earnings share impact about the $X.XX. diluted allocation this capital XX repurchase on be share assumes per regarding non-GAAP all count be at earnings full currency outstanding. that year results XXXX a rates, range guidance continuation an million for to basis, our on growth foreign of a average rate full program expected of $X.XX Our year XXXX, together Rolling about is will diluted are current neutral. a per of projected At share and shares share

of to quarter we range sales $X.XX. assumed as likely Looking and diluted currency is $X.XX X%. sales of very XXXX, from strong due earnings rates, in of constant per these to At the today’s about growth to fourth moderate areas. the a benefit affected new standard, with in expenses X by estimate impact factors X of growth to increase a the as the against quarter in $X.XX fourth positively translation range we expect quarter accounting comparison basic quarter another X% line well to expected share Combining of fourth at hurricane currency impact top tax

like to Chris? Chris. turn I’d Now to back the call

Christopher O'Connell

Sherry. thank Great, you

move we core in businesses performance and our into fourth delivering operating continue As the we execution on our emphasize will to quarter, objectives.

we one Investor yourself if get Operator, additional stated, please. balance may to we question seek business. first have leverage question will growth, contact lines the limit one rarely you now we please we will have follow-up to and investment operating As the questions open in and to team. our the have please that, after phone Relations so we able Q&A. are and everyone’s call, With the for question,

Operator

Thank you.

Our first from Tim Fargo. from Evans Wells question comes

Your line is open.

Tim Evans

Can you’re give for a GST and in QX. big also impact least Hi, perhaps impact the was expecting quarter sense thank you for and us India hurricane you. maybe the the how that at hope

Christopher O'Connell

Tim, India question. about growth that India you we business natural GST the we natural Americas quarter. impact quarter hit Sure fourth QX. that the but in as estimate majority these top saw in and thanks know in working Latin fourth of and less think than we but one-timers we you in for and split situation third our risk that a we speak commented, by equally woods, to call where through between really know that the to as in the X% two that the the bit steadily recover US the roughly was be a rate of From be delay somewhat hit while took region over that’s it for the disasters some line the shipments. quarter refer may is different we the will three a the those the and in and not factors in little or out the GST simply We the that look was hopefully the really orders that standpoint, coming expect completely will QX quarters disaster America to We of shifts

Operator

Thank you.

next Our JPMorgan. coming question Tycho is Peterson from from

Your line open. is

Tycho Peterson

bifurcation you’re Hey bit want ask seeing versus Chris, kind the a growth to of I of US. little Thanks. about out Europe the

and of that I does quarter, here particular stands the bit certainly a little growth an it that down driving the slow Is sub-segments market? the this that in comp. know conversely kind mean out in feel US, XX% noticed You easier I dragging Europe are versus sequentially then US

Christopher O'Connell

yes. you the US bifurcation There make is and the business. first Europe between and Thanks, know more as pointed question. comment for definitely the out a Sure, a pharmaceutical Tycho you I’ll on

trade. As the operating a pharma global here short-term tax know certain now environment what you of by very we The more and is is and on larger multinational obviously our friendly the business right regulation Europe, are seeing and and the business and that’s more driven favoring. company sort in pharma and environment experience clearly more

stepping and which industrial and U.S. was now. we seeing and of have think the the these right their cycled And saw call, improvement QX U.S. like sector, that was a does but the and tone so, little said than better than as both Europe and in in U.S. mode, Europe, wait encouraging. like QX and that’s what we’re between feel activity was the in In in you we we certainly bending in companies that the see saw growth bit know actually sometimes definitely QX a a better sequential we U.S. out so purchasing its hopefully of the QX, we’re

performance is government now, pretty broad-based industrial and right both in growth Europe. in also a and U.S the saw and in Our academic we

tough really minutes the in we’re we as trading-off encouraged pharma pharma saw pharma think demand we Europe the some near-term U.S. said really obviously we healthy, is the those growth on shift quarter pharma is U.S. despite versus with of ago. overall, and that So few like well we absorbing very but demand as about one-timers demand that spoke just the comps was a question

Tycho Peterson

customer get better just on if little the feeling bit or about a are from to increasingly I wondering so highlighted a follow-up, base comment of of I just comment customers Okay. worse, you headlines you could lot know biopharma, the what you as know you if generic the on you given on, broad and as And then like well? side there we hearing questions know those where on molecule a large but are am you talk I some I there, can

Christopher O'Connell

that is of and and been from really biopharma very past as to initiatives. environment. strong system in their consistently the headlines seeing themes demand we alluded continues larger what bigger the the than our about and GST again strategy categories we broad to Yes, more quarter, there, focusing generic what And in of been all But based, at solid of call, our and and see is much I had the have day investments function market for again, the that certainly it the out couple continue companies the has pretty despite Indian were business to some volume some as generics business innovator There similar difficulty, good. see biopharma years, implementation of with dislocations Tycho we new into in I conversations, is companies. in in obviously has think analytical investment a is to win the techniques short-term seeing companies mid-sized saw new mind the some subsequent even of been to the that generics a lot startup companies generics in but companies the the heard been I that keeping in year have continue you investor have is and our say analyst on with the highlight some and majority market new production we U.S. over

Operator

Thank you.

Deutsche from Leonard Dan from coming is Bank. comment or question next Our

is now line Your open.

Dan Leonard

about margin how thinking on head opportunity Chris side you you the as XXXX? are into you, the Thank

Christopher O’Connell

margins. in continuous approach the is margin margin our to and value creation out call Sure, on for look the philosophy pointed as model, at obviously operate strong is improvement, I we

and we concentration and operational attractive where any and not of modest we our in initiative said optimized before, a improvements. I is think can markets our unique model, achieve reflection end think a we it's highly of operational we have improvement ongoing way being technologies so the profile business I have and strong margin reflection a in As underway,

you and so quarter both we’ve at operating think basis to mentality I going delivered that our a year-to-date currency is look If a and continue the into P&L and reported leverage ’XX. constant on year-to-date, basis in

like We’re not giving really yet up industry call. particularly investment year-to-date some we’ll and guidance Maybe reflection will P&L a in another I’ll innovation. both just leverage about R&D I a we’ve we solid improvements the continue mean a of to looking and currency moment organic But quarter-to-date looking SG&A future R&D. that January and the in the take year investing to modest is line on of really while but things that ’XX R&D growth is you on be lead revenue at operating and drive desire do certainly year-to-date continuing invest the while that’s raise to strong our one in most while XX%. achieved on comment our that constant to to I in about nice basis our a of

Operator

Thank you.

question Bruin from America. de is Bank Derik Our next of coming from

Your open. line is

Derik de Bruin

morning. of good couple Hi, questions. A

and there you that looking I from be, buy into the of tailwind overseas posed? the use talk be one is ’XX follow-up on I mean What shares doing the thoughts of first how is what to sort tax cash some are obviously would dynamics the you Sherry reform some comp cash. this sort what at would obviously about is you’re what a can to I able question that to year. going would guess mean help you’re there your assume repatriate you’re translate based talk you just $X.XX this? I over about offset and questions The back stock a to of Can initial question

Sherry Buck

to we’re about team Sure, I'd reform well XXXX. if operating to like we’re at lot as good us add and and talked and we free next stock tax compensation it and would tax to question sheet is don’t in the of would else? share look is more optionality the better and bit that’s rate can of expect it’s say little return going as as at I put and early anything reform program think you’d our up a for this our have details on switching to know for here Probably impact for the options to us will fine debt we a a we comments provide emerges shared remain this lot repurchase tax to Chris a too closely best some that on meeting a next the think on guidance our shareholders. I reform, consistent of really us with looking have year that to we Chris of is then business and And we the as year. seen and continue in important the have mid-teens tax hoc the obviously that on finance and we you’ve helping our deploying question we watch your invest looking at ad we a to quite as profile bit details. looking in our arena. committee we also an have And but balance for with point it about cash looking when And as internally

Christopher O’Connell

That’s well said Sherry.

Derik de Bruin

Okay, question. a follow-up

little on year have then a the what’s now you my you’re about it’s benefits by and like EPS the like math. by walk the $X.XX Just increases going I bridge. year. with X% walk then underlying of is would talking and it's through the looks full increase headwind bit high that initial my obviously business. FX math bridge of a guess upon for EPS lines not a sort thought math, as wanted as It you're full know we lark, It about just you looks negative based the sort before to of through

Sherry Buck

a on through as we're Chris EPS some look looking currency and just in about the mentioned the really taking we’re so of constant bridge, FX some operating our of we in of earlier, of so Yeah, as at we’re and business the following investing the at investing basically the through the trying FX our business. and upside guidance, balance R&D leverage to bit and little the QX XX% year-to-date up benefit basis, a

Operator

you. Thank

question next or Our comment is from Doug from Cowen. Schenkel

Your line is now open.

Doug Schenkel

and provide was food, could morning. industrial any within revenue and by sub-segment What by each within growth each the trends Good you category relevant details core geography? on core environmental sub-segment

Christopher O'Connell

to commentary. going of not we’re to general but I’d think breakout I you those back level that at some details Doug, granularity, point go our

many was territory and of India quite was all smaller, well tax those categories industrial and part number balanced know materials business with industrial it but major due characterization environmental industrial smaller actually was bigger U.S., across China were in positive really the GST these business. our geographies, balanced implementation, are in across Our and Europe and a food well different slightly as to pharma negative and on you and in much

quarter also So, both positive I U.S., industrial year-to-date territory results and in the Europe. but all at last and results, on in would just the results XX-month look in China

Doug Schenkel

Okay.

back to flipping biopharma. Just

are comparisons, how lagged certain a be the year couple a comfortable This your tools the revenue shifts of quarters. also a of at company group you share classes function You has for Chris, your are product competitive year, concentration growth that least broader on but last had specific good that and said the factor? simply biopharma may not

Christopher O'Connell

our consideration growth as taken has over but as we be year low you at pharma Yeah, been pharma looking really both I comparison Doug, as two solid growth teens last alluded when to the well basic am quarters last X% almost XX have prior confident guess into at of I in and to year-to-date rock we look business months any sort in best and period. of almost you’ll oldest rolling growth those the tend point. period doing SDI do the competition, data if obviously and standpoint a well sources the I think market see share that. at from can from the pharma our to different reinforce surveys to you share and to like all are same results we survey of over any compare rolling that We rate,

As sticky be in markets. you very can know share these

high that’s really positioned great with our future. by grow And only just multiple utilization and a the also technology into competitive together our UPLC mind that job resolution also we we empower innovating Mass invest shares, LC chromatography in that world, advantage data is about on but in some for technology holding seen market systems, product not what’s in spectrometry HPLC a share visibility base line us business, there gives We got continues but enhanced. turn very think that of we then categories done categories of well recent the continuing like which have where we keep in headlined gains we standpoint, strong very to good own our LCMS done I as we’re broadening in two years, share of core for technologies be continue and market the happening are well [indiscernible]. and share earlier have to certainly will some are of pressure new a In have two-thirds the the major believe we from And and that CDS, with other of have the those especially talked in for about direction. the heart to [indiscernible] instruments and we these the

question try about are. share we feel much the to do we as study good but as we we So, can where

Operator

Thank you.

next or is Meehan Our Jack Barclays. from comment from question

is open. line Your

Jack Meehan

trends Chris, of think quarter, was a on fourth bit as the guys. a the from morning a good little and industrial TA result Thanks, wondering, elaborate you comp in about the you great quarter, tougher could there. and obviously I

be talk could the great? that you If about setup would

Christopher O’Connell

a has as industrial the XX TA is good industrial did performance good categories. that the Waters digit a of the developed had year and of for we the you this allude out So, TA those you really strong year know all as maturing mid-XXXX still that been which instrument winning you’ve in to say really would portfolio been is point of this X% just analyzers between that’s we’re have growth long fourth different has steadily has actually tiered discovery TA saw quarter the thermal believe reflection I out in a growth in reiterate and balance and double to over as year around out a as of been year, well we seen and industrial last industrial strategy and last course naturally instruments the you has all line thermal TA this overall months we process And been because on our product our as has X% since the quarter come a story year-to-date of of year. really strong applications. has rolling

these beat strength know are I of about has broader of bit product a things some a give [indiscernible] recent some in and a footprint of of those the force beginning drum like and in a of group acquisitions the little even you of small line electro TA think us we’re more past also tuck-in and bit also the performance TA, talked acquisitions industrial encouraged markets. we’ve to scale by lot the and should of as a

pharma aspects course we and I over watch that’s good have out the came think of obviously growth when setting we into played were and So the closely, out one year think satisfying more this far. we of balance industrial I the between and the year-to-date to so what’s of year

Jack Meehan

then gross about the Sherry, otherwise. And XX that mentioned is some driven year-over-year that impact you to you the would or market whether just got one end just headwind mix about Could on talk of imply product in that its FX Great. margin result? about quarter, flat or bp for

Sherry Buck

gross of any Sure, a pushes we have question pulls on margin. lot and the

cushions operating so us variances a on of and margin. headwind the of but on the some service a you So there dynamics we quarter margin kind that’s it, mix manufacturing positive it had as strong helped some pretty and helps our to were gross as know

now improved little with it the total been US is has it of also a a being, bit Our that but of bigger there gross part the headwind on margin. is performance,

and us put to things the gets you with those that So, FX quarter. margins all together the for gross our

Operator

you. Thank

Steve next Stanley. Our from comes question [indiscernible] Morgan comment or from

line open. Your is

Unidentified Analyst

thanks. Hi,

for one Sherry, to play get have revenue some coming into recognition particularly whether just and a is impact then is the of housekeeping X% if currency see probably new those Sherry, like next that to be they’ll had don’t look any for to also service going I know, next couple it rev year record then a for what to Chris. have for are I for there take then seems on counting? rules then you’re at positive And anywhere and I thinking? Sherry sense you items And First a again, is to chance maybe any year the Chris. line, X%, bottom close of one for

Sherry Buck

to line impacts impact been point recognition, globally on the while would our it we has team of revenue service the we’re our of revenue contracts the in on or understand complete material on and work be bit time. this at Sure, quite a that having totally that everything just assessment doing with our aren’t current not

about next for question housekeeping year. other Your FX

we too not just yet. in would today’s X% little giving to we do be based X a looking too say thinking But, rates it are since be wouldn’t FX but in call XXXX, So, at will I tailwind, guidance for as rates. early positive XXXX early slight today’s would to high that be obviously I on a as or January,

Unidentified Analyst

real I’d pick to about you under And of next can Chris think know thinking just topline and then look that ask might here. the let up excited and quarter I’ll you step it's investors you that’s Sherry, question, growth over that? time a a here through thanks Okay, want Waters like a others it appreciate. to details in thing horizon, don’t love you if I the of Q&A, covered Thanks. you open that is a really simple of kind lot in have one What about the we driver people year,

Christopher O'Connell

needs. have material it’s we the a with those and gained together in strategic second conference, of makes world that been that one Mass of and work is inexorable vertical to well. Directors Board in desire think around a growth separations and that I little even business type analytical materials the or all at the the things, New have first deeper and little routine a week function mentioned the it I its out particularly all when say is is a into of workflows process, and of sort I top have for had more we and I LC last But of other really accessible open Mass been is we on think I and use And the things there opportunity look I applications think just as this informatics deck, excited big Sure, that the we very appreciated, that that hold but completed two there with informatics chemical thanks as which a time. for I in of lay program we this previous discussion the as regulated technology opportunity and could structure plus the move rigor rise comply our bit period foundation time workflows some applications market chemistries is other behind position course markets, a for specificity sustainable cards is most spectrometry very about list spec all of long is things of in [indiscernible] that lot is Mass out opportunity and we I into our bio-molecules to and we you the of talked strong the overall in development something settings, just great as put your the what regulation the have that including spectrometry a am integrated and about around really in think compliance opportunity some know there categories precision we and whether roadmap, long opportunity planning And plans I a is for our more think the about I drugs, deeper food at and came more have more there, Steve in York. years more our guess appreciation gain there of than in up opportunity. to question good job now, is our our insights for I of in a really at to our that and the annual a have this range have just users making look think not great our technology we I’d just Pharma to in molecular

as And management and the very get to but opportunity growth how know to up the that in continue to investment that’s long a my also expansion so that’s opportunities. it's a but strong the bit a be that’s so, I disciplined to answer with business, results balance these mind, the of and after deliver us we on team on margin

Operator

Thank you.

next is Citigroup. from Dan coming Arias Our from question

Your line is open.

Dan Arias

Good morning, can thank color put spec, comments you. within some Mass you to just there. Chris, your

expansion the application the You in came of MS. to base back

more looks the this higher or by difference? or curious a growth point of is is research how routine it discovery there usage split testing from Just at fact in So, the you’re seeing segment?

Christopher O'Connell

We’ve spec that mass Yeah, I been and actually Dan by our we’ve this the in based. both it’s as note, had performance year is strength year. in year-to-date and highlighted and broad good quarter spec a encouraged question a solid mass the

working to We its are been to way in beginnings of downstream robust, product I markets. movement the prior the the has there and in seeing in also it's But alluded question QC. think even heart about of spec what the robust of applied the I even into been discovery development mass but QA further

shown and some strength is in the food chemical as application areas particular with and in portfolio in TQS [indiscernible] its well. tandem TQSX the Our of quad Micro

more beyond been broadly some of view an that outside utilized somewhat again, the its simple known playing traditionally see do out for. coming mass much more into I that tool really go research in of overtime the applications a well formats company, So in as spec

Dan Arias

X% then just what setup the it is the one biopharma more class. if And quarter. believe this at the coming ask helpful. was which I Okay, just for quarter, customer than I I maybe comp within is could less question If the on look

to biopharma in line a look think year you is XQ, think finish couple it? in done you X about could you’ve the ahead or at with So, of you to I the way year-to-date mean just do X% higher points if still what

Christopher O'Connell

where guess on sort the that comment I we we of markets just very at business. and basis said. much business historical for Dan we’ve rolling say continue of to I typically And play been know tracking we a look that at what strive a dynamics have into we we rate You can. is we which it strive overachieve the as the at long-term continue will which I always think that growth look to And global to as and obviously year-end

we point We’re we’ll attractive a everything the and think assuming in optimistic this take but guidance terms think so to is continue healthy US attractive cautiously cautious increasingly but market very not we’re is overall the goes and we main market our point that in the step at step right and of looking by pharma forward. is

best And so, in we’ll just it can. focused stay the getting continue we laser to on

Operator

Thank you.

comes question William Amanda Our Murphy from next from Blair.

line Your is open.

Amanda Murphy

of Alright, good similar the terms morning. the in just Dan to I question actually had side business. LCE a of

you’ve in in obviously that’s growth talked just our So results about generics about biologics. talked to or strength drive and how going continue

of so mix point at understand in kind could between kind sides is just kind from the this it does install of if then changed, the how you some contribution alliance at base how the the help and looks to point? do I what change and look both expect what’s it wondering this like has product growth that to like UPLC the how of of us platform you So, and

Christopher O'Connell

molecules bridge forget of robust our point orientation transformational things it's pulling Amanda, know we why don’t continue is and system by actually systems bigger as engineering the pretty Optical this empower and more particularly platform alliance a that to enhancements units, just still much and it's an to a informatics systems new offering chromatography platforms terms that and talking pretty but which have data LC component we uniquely system the that’s we so things the HPLC about plus really is and really other PLC of see balance customer the that can serves continue platform the at the portfolio so you detection is wide together. good engineering Sure variety because system a business that a a can on its methods systems and question do alongside those to the types LCE hybrid we us well develop that’s overall in UPLC as time of not hear of solution HPLC LC [indiscernible] and and and good our all marketplace in that you system plus also and between as those generic in actually in

Amanda Murphy

and on okay I also it, another then question China. Got

So, quite at that, is growth one curious that contacts how of of big obviously driver you, of you market going talked thinking for point any just if growth past medicine. market could a areas kind think this the that how in had well, about was much and is growing you the is other be the again as driving being but as you traditional about of China forward? I is around

Christopher O'Connell

the TCMs hard to question. our an Yes, does as around genuine point medical are continue think the amounts definitely that’s that traditional or the generics, small impress of its breadth TCMs. in therapies TCMs drugs always a and within the big methods in yet food a China a and to to has continues and of markets, but regulators less that’s on in growth, niche Chinese within definitely other as testing about applications the has labeling in labeling products prescriptions and it’s well to get so quarter strong even is requirements TCM I that to data lot But and I seem and quickly TCM predict aspect also me part that a as of the but long there market, concentrated good alongside itself it's of for now. China. had actually been type than is more and for be in very food that a balance pharma other the a important a I'd growing materials of that Chinese how the are and we in diversity interest enhance love TCM takes than food TCM a those equal see and and that and requirements around XX term think thing testing in innovator could market we throw see of and and Company, we China year-to-date requirements China seeing terms have story the and categories the is pharma unique in a China, for markets population testing the hear last increasing be China and arms pretty tailwind, are regulation concentrated the months great lot to is

Operator

you. Thank

Our is next Patrick comment from Goldman Donnelly Sachs. or question from

Your line open. is

Patrick Donnelly

think saw you strength government what you aren’t saw thanks. exposure a relatively you the areas guys small but some the and of notable Can U.S. the just kind maybe where Great of maybe Chris, proxy saw there. focus best particular here? your given market for on certainly lab budgets I academic with just talk through then growth you

Christopher O'Connell

XX year-to-date revenue. X% Patrick that actually not of was a rolling last exactly our and you that type well the proxy that quarter prior great were said overall. of roughly you of again no quarter the though its is it overall I and months at which XX% range year-to-date more think period or in a digit Sure, in right, built are mid-single on for is good which you look low grew market, we’re market It we characteristic the that more if to definitely

academic the is pointed for out somewhat market we As before, and lumpy. small us

Omex and lot greater pleased get of in just quarter-to-quarter healthy strength get on of have particular the greater or seen bit, don’t do areas a the metabolomics will we be because with overly that see interest if and metabolomics we’re particularly and we better and a the the goes research and steady research assays continue down work, because of community there But in pretty and microbiome of a biomedical So, position market in particularly we the biomedical there a period. that in exercised understanding business related bit rolling from the type investment think continues we and have variation and over of some very I emphasize up to our drumbeat a to appetite for research.

Patrick Donnelly

few like questions you around you feel in towards couple pockets you of Okay, you of obviously at kind going we’re makes digit high I but just X% maybe when do of on there? quarters about and one on a we’re of longer-term there growth X kind look kind that, cycle forward, little growth single or of this you X%. last feel And where pharma growth, the market the rate you feel growth the I see of for you at look opportunity when and do hang to reaccelerate can that more that a know talked while the mean sense.

Christopher O'Connell

that rates. trends rely do get we see I that better had safely as that fairly do historical long-term think from some I and of of we’ve time-to-time never feel get exactly overall time-to-time on you now continuing we we’ve possibility years think terms accelerated will but in you quarter-to-quarter to of historical I pharma that mean like our and you us now about good we trends that in too know said forecasting and don’t right far over from growth know, the the tips market ahead we the from as and through to underlying give growth if

to that and that it pretty happens we some time-to-time So, acceleration. has happen happened it's get predict hard but to from to ought when continue

Operator

Thank you.

is from Leerink Partners. question next or Our from comment Puneet Souda

open. line Your is

Puneet Souda

quick Chris, to the the thanks X A mix. assume my India I still X% GST, of questions. taking clarification Hi has for just on

perspective on the end? still or them for for the continuing of alliance generic tax the they market some then negative a a are shifting is and So, or categories that from if GST tax GST largely at UPLC benefit you to and it if be them is accounted customer the buckets, it to once look and changes a to is

Christopher O'Connell

X% clarify its more small Yeah, and on but the the [indiscernible] is thing well of GST is really. government demonetization. India as a GST quick X mix and just a implementation applaud thanks the economy X% in and things. question that’s X% of bull to pretty and like couple measures for of the the to actually important a of yes, to versus and range our India India India as of and just really difference I

customers economy up think India systems and the to in to their with doing systems. our going that I delay could shipments to more to way have systems their implementations our The some laws is pave putting compliant forward. related what orders for in and new stability that the changes is for now is right match be purely to

particular in of capability Indian the stable example a I of or forward long see don’t really, we it will Q work more country going any term transactional of provide So, base than that working as a through But through customers certainly other ongoing which will as real working that a and kind our tailwind catch economy it's are of headwind, think we’re another see. very we foundational through on the benefit the I attribute overtime. that and will that of time, an

Puneet Souda

and are at as would impact as there as overtime Okay, us of specs thanks idle, for that guidance mean they mass some of that. to back replacement replacement and And are quickly largely understand, trying expecting, mass sitting so just specs, tailwind for well on been you is any that the the are and wanted LC Hurricane that I any accounting you the essential uptick to ask sitting these expectations? and just some if understand I in coming go because end, from in of bad rule are detectors your on instrument

Christopher O'Connell

road pretty the and of these needs actually really that employees of there. on I accelerated opportunity it in way, the obviously replacement beyond helping about great, employees in getting if some more focused we’re best it we’re and that thinking have serve conservative customers and is areas our and that this and operationally the we’re assuming think we’re in our thinking people work to our up and and our we we I focus tailwind about mean and customers, on doing results ravaged not through or not we’re really down back opportunistically Puerto of running but on our any kind additional some Rico purely can customers.

please John here, I we quick two one two more think time, ones for operator. or have maybe So,

Operator

you. Thank

Brandon from Couillard Our Jefferies. is next question from

Your line is open. now

Brandon Couillard

for quicker contribution just to revenue quarter, from extra do What and confirm, an was sort items. correct? in the the One third quarter, housekeeping M&A day of the fourth Thanks. Sherry, you have in

Sherry Buck

in outlook Yes, then quarter into fully factor earlier his our from mentioned coming comments. contribution so isn’t small the guidance. Chris there as TA of we fourth just And in and that M&A a through very kind and extra day

Operator

you. Thank

Our Willoughby Steve next question comes from Research. from Cleveland

open. is Your line now

Steve Willoughby

Thanks Steven here.

your Just a similar quick was X% was one Sherry, it's Chris. here have for swing have when in quarter so X% right FX from make to on your FX $X.XX right, sure a a believe a for positive guidance results. penny want Sherry looking, and quarter. a then I to in FX and a just of kind headwind positive, then question math I the little just that $X.XX do a for I for am I to third

Sherry Buck

that’s Yes, correct.

Steve Willoughby

older Okay. about Chris you the into any on overall comment and products, just in of are product all that fits what wonder And new growth QDA its of kind how pipeline? driving products, the kind of then of whether products could comments product your new kind if terms your vitality days these

Christopher O'Connell

to very That chug with empower am answer chromatography source very on data. reliable but does I Sure, really impressed continues a will Alliance, give quarter mind, of if actually our move -- products to by an like growth. be of quarter HPLC comes of contribution Systems precise are along you it the old because and balance we too to that, I won't around

of solid that’s a will which of a the see call UPLC market I products medium also been to the year in really a said few that’s sort and I uptick Micro, been for good continue in We like mass on as what have Like arc been like some well. specs [indiscernible] QD is about technology TQS and combination but years old. QDA, the market

a launch So, biggest your beyond the thing hold lot is product not all really to see about measurement. this. up of we their and have and cycle try work of how way think of standards technology we lot do strong One actually of three products technology new believe those have in two, gets in a that and balance, of just sometimes in the a leverage traction and technology coming continue of lot to the do as in and but four categories these a some pretty I grabs you ’XX we’ll actually to and aspects impact more in and technologies marketplace of

think product and future. our a I’ve and for we offering investment position priority one pretty we said is number R&D the good anyway, many a times So as today in have for growth product this vibrant

the So our thank XXXX, first results through anyway, P&L the from all with digit our headlined of combined you. that In deliver and with want share quarters consistently double for to to with we’re by revenue the finish you strong maybe questions pleased organic ability management questions disciplined with conclusion, say per three we’ll earnings to great of deliver just growth growth.

out close strong our competitive position focused remain execution conditions with combined that XXXX, we we and success. As on support market feel continued

our and So, thank team, for which We XXrd updating behalf support forward XXXX. progress we day. and on of XXXX Thanks, during holding interest call currently January Waters. on look I’d entire our like to in to QX on you great you management our a anticipate our have

Operator

participation, Thank you this Thank disconnect at you. That your today’s time. concludes may conference you for call.

Waters (WAT) 24 Oct 172017 Q3 Earnings call transcript